As long as 7 years after treatment initiation in the pivotal ANCHOR and MARINA studies, 68% of eyes had signs of active exudative disease and 46% of eyes were on ongoing anti-VEGF treatment [20] emphasising the chronicity of wet AMD. This evidence concerns the gene VEGFA and wet macular degeneration.